

# Game Changers

## ORAL DRUG THERAPY – IMPROVING SURVIVAL IN MALIGNANT MELANOMA

Dr CH O'Neill, Dr J Carser

Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Lisburn Rd, Belfast BT9 7AD

The incidence of melanoma continues to increase. In early-stage disease, 5-year survival rates with surgical resection exceed 90%, however, stage III and IV disease has a higher risk of recurrence after resection, and many will ultimately die from metastatic melanoma. Since 2012 there has been a rapid increase in NICE approved therapy for patients with metastatic melanoma, with long-term survival now a reality for selected patient groups.

Novel oral agents targeting the MAP kinase pathway, specifically oncogenic mutations in BRAF (present in approximately 40% of melanomas), have enhanced outcomes.<sup>1,2</sup> Treatment with the BRAF inhibitor, dabrafenib, plus the mitogen-activated protein kinase kinase (MEK) inhibitor, trametinib, result in clinical benefit in over 90% of patients treated (median survival now approaching 3 years). This combination is routine practice in Northern Ireland, allowing treatment of severely unwell and symptomatic patients who previously may not have been suitable for chemotherapy, with often rapid resolution of symptoms within days to weeks.

Furthermore, this therapy has shown response rates in excess of 50% in patients with symptomatic brain metastases, improving symptoms and quality of life, providing options where once there were few and has largely superseded whole brain radiotherapy in this setting.<sup>3</sup>

More recently, the adjuvant COMBI-AD trial<sup>4</sup> reported that patients with completely resected BRAF mutation melanoma treated with dabrafenib/trametinib for one year had improvement in the rate of relapse-free survival at 3 years of 58% vs. 39% with placebo, as well as improvement in survival at 3 years of 86% vs 77%. BRAF/MEK inhibitors in the adjuvant setting are expected to enter routine clinical practice following regulatory approvals.

1. Long G, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. *New England Journal of Medicine*. 2014;371(20):1877-1888.
2. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. *New England Journal of Medicine*. 2015;372(1):30-39.
3. Davies M, Saiag P, Robert C, Grob J, Flaherty K, Arance A et al. Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *The Lancet Oncology*. 2017;18(7):863-873.

4. Long G, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. *New England Journal of Medicine*. 2017;377(19):1813-1823.

## RADIOFREQUENCY ABLATION AND ENDOSCOPIC MUCOSAL RESECTION IN TREATMENT OF EARLY NEOPLASTIC BARRETT'S OESOPHAGUS

Dr B Callaghan, Dr I Mainie

Belfast Health and Social Care Trust, Lisburn Rd, Belfast BT9 7AD

Barrett's Oesophagus (BO) is a precancerous condition, associated with chronic gastro-oesophageal reflux, resulting in a change of normal squamous epithelium of the lower oesophagus to columnar epithelium. In non-dysplastic BO, the cancer conversion rate is 0.9%/year with increasing cancer risk of 9.1%/year with low-grade dysplasia (LGD) and 25.6% risk with high-grade dysplasia (HGD) over a 3 year period.<sup>1</sup>

Within Northern Ireland, endoscopic therapy for early neoplastic changes has offered patients a less invasive treatment option with curative intent in comparison to the conventional surgical intervention. These include radiofrequency ablation (RFA) of dysplastic BO and endoscopic mucosal resection (EMR) for nodular BO as per NICE recommendations.<sup>2</sup>

All cases are carefully selected and discussed through the regional upper GI cancer multidisciplinary meeting prior to onward referral to an advanced endoscopist competent in performing these procedures.

To date, a total of 282 EMR's have been successfully performed on visible oesophageal lesions and a total of 238 RFA on dysplastic BO with curative intent.

These procedures are generally well tolerated with minimal recovery time and same day discharge. They are performed under conscious sedation and have much lower morbidity and mortality in comparison to an oesophagectomy.

The future reduction in oesophageal cancer risk due to the fact BO can be eradicated highlights the importance of this therapeutic endoscopic intervention for the future.

1. Fitzgerald, R.C., et al., British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. *Gut*, 2013.
2. NICE, Endoscopic radiofrequency ablation for Barrett's oesophagus with lowgrade dysplasia or no dysplasia. <http://www.nice.org.uk/guidance/IPG496/chapter/1-Recommendations>, 2014.

## DUAL ENERGY SINGLE SOURCE CT CORONARY PERFUSION ANGIOGRAPHY – A HELPFUL FUNCTIONAL ADJUNCT TO ANATOMICAL INFORMATION

Dr A Canning, Dr S Hughes, Dr JA Purvis



Depts of Radiology and Cardiology, Omagh Hospital and Primary Care Complex, Western HSC Trust.




Fig 1. Short axis view of left ventricular myocardium showing decreased perfusion (blue/purple colour, white arrow) in the zone of previous myocardial infarction.

CT coronary angiography (CTCA) is recommended by NICE for noninvasively assessing coronary anatomy in patients suffering stable chest pain.<sup>1</sup>

CTCA is however, an anatomical test and yields no information about blood flow in ischaemic myocardium.

Our new General Electric Revolution HD CT scanner allows “mapping” of iodine-based contrast into myocardial tissue. Images are acquired at 2 energy levels during a single scan by passing a filter in and out of the x-ray beam. This produces a map showing the concentration of iodine in myocardium consistent with blood flow. The scan is then repeated using a stressor agent (such as adenosine) to induce ischaemia.

Comparison of rest and stress images outlines ischaemia or old scars from myocardial infarction. The map is then superimposed on the coronary artery images to produce composite functional and anatomical information. Total radiation dose is similar to coronary angiography or myocardial perfusion scintigraphy.

In the accompanying rest image (Figure 1), a patient with previous right coronary artery stenosis treated with stent complained of further chest pain. CTCA showed a patent stent (yellow arrow) and the superimposed perfusion map showed a defect (white arrow) which did not enlarge with stress – consistent with old myocardial infarction scar only with no ischaemia.

1. NICE guidance on investigating people presenting with stable chest pain. <https://www.nice.org.uk/guidance/cg95/chapter/Recommendations#people-presenting-with-stable-chest-pain> Last accessed 1<sup>st</sup> December 2017.

